Naples

• A study to evaluate the effectiveness and safety of Dysport® for the prevention of chronic migraine in adults Ended recruitment
  2023-504827-17-00 5 2024-03-18 Chronic migraine
• Long-term safety and efficacy evaluation of subcutaneous amlitelimab in adult participants with moderate to severe asthma who completed trea … Ended recruitment
  2023-503385-24-00 4 2024-03-12 Asthma
• MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer Ended recruitment
  2023-504816-14-00 5 2024-03-08 Endometrial cancer
• A Phase 3b Study of BMS-986346 in Lower-risk Myelodysplastic Syndrome Participants Ended recruitment
  2023-504541-31-00 5 2024-03-06 Myelodysplastic syndrome
• Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC): Evaluation of the Optimized Dose, Safety, and Efficacy of Livmoniplimab in Co … Ended recruitment
  2022-502948-13-00 4 2024-03-01 Hepatocellular Carcinoma
• Patient Preference for Route of Administration with Intravenous Infusion Switch to Subcutaneous I-O Regimens in Melanoma Ended recruitment
  2023-504515-33-00 4 2024-02-19 Melanoma
• An international prospective open-label, multi-center, randomized, non-comparative phase II study of lutetium [177Lu] vipivotide tetraxetan … Ended recruitment
  2022-503040-41-00 4 2024-02-09 PSMA PET scan positive Castration-Resistant Prostate Cancer (CRPC)
• A Study to Evaluate ABP 206 Compared with OPDIVO® (Nivolumab) in Subjects with Unresectable or Metastatic Melanoma Ended recruitment
  2023-503288-40-00 5 2024-01-26 Unresectable or Metastatic Melanoma
• Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants with PD-L1 Positive Recurrent/Metastatic … Ended recruitment
  2023-503428-24-00 4 2024-01-19 Neoplasms, Head and Neck
• Comparative Study of Oral Atogepant Versus Oral Topiramate to Assess Adverse Events and Disease Activity in Adult Participants With Migraine … Ended recruitment
  2022-501172-25-00 5 2024-01-17 Chronic and Episodic Migraine
• TACTIVE-U: An Umbrella Study to Investigate the Safety and Antitumor Activity of ARV-471 in Combination With Other Medicines in Adults With … Ended recruitment
  2022-502231-19-00 9 2024-01-02 ER+/HER2- Advanced or Metastatic Breast Cancer
• Tuvusertib (M1774) in Combination with Cemiplimab in Participants with Non-Squamous NSCLC (DDRiver NSCLC 322) Ended recruitment
  2022-502010-85-00 9 2023-12-20 Non-Squamous Non-Small Cell Lung Cancer
• A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatm … Ended recruitment
  2023-505120-59-00 5 2023-12-19 Moderate to Severe Plaque Psoriasis
• Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer (DeLLphi-304) Ended recruitment
  2022-502669-14-00 5 2023-12-18 Small cell lung cancer (SCLC)
• Public Title: Study of Lurbinectedin in Combination with Doxorubicin versus Doxorubicin Alone as First-line Treatment in Participants with M … Ended recruitment
  2022-502975-45-00 5 2023-12-12 Metastatic leiomyosarcoma
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Satralizumab in Participants with Moderate-to-Severe Thy … Ended recruitment
  2023-503309-13-00 5 2023-11-29 Moderate-to-Severe Thyroid Eye Disease
• Phase 3 study of perioperative dostarlimab in participants with untreated T4N0 or stage III dMMR/MSI-H resectable colon cancer Ended recruitment
  2023-503265-27-00 5 2023-11-23 Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Co
• A Study to Evaluate the Efficacy and Safety of Sefaxersen, an Antisense Inhibitor of Complement Factor B, in Patients with Primary IgA Nephr … Ended recruitment
  2022-502102-32-00 5 2023-11-16 Primary Immunoglobulin A (IgA) Nephropathy
• A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M … Ended recruitment
  2022-501863-41-00 5 2023-11-13 Subjects With Stage IV or Advanced Stage IIIB/C Nonsquamous Non–Small
• A double-blind, randomized, placebo-controlled trial to test the efficacy, safety and tolerability of Dimethyl Fumarate in Friedreich Ataxia … Ended recruitment
  2022-503016-16-00 4 2023-11-10 Friedreich's Ataxia
• A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’ … Ended recruitment
  2022-502966-26-01 5 2023-10-27 Sjögren’s syndrome
• A study to compare the study treatment darolutamide in combination with androgen deprivation therapy (ADT) to placebo in combination with AD … Ended recruitment
  2022-501343-33-00 5 2023-10-18 Biochemically recurrent prostate cancer
• A study to test whether spesolimab helps people with Generalized Pustular Psoriasis (GPP) who need treatment for repeated flares Ended recruitment
  2022-502128-38-00 11 2023-10-11 Generalized Pustular Psoriasis
• SIERRA: Durvalumab and Tremelimumab as First Line Treatment in Participants with Advanced Hepatocellular Carcinoma Ended recruitment
  2022-502012-37-00 5 2023-10-06 Advanced Hepatocellular Carcinoma

Showing 697–720 of 1,177 trials